David A. Siegel Heron Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 823,871 shares of HRTX stock, worth $1.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

823,871

Previous 811,371 1.54%

Holding current value

$1.43 Million

Previous $1.61 Million 21.93%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.06 - $2.12 $13,250 - $26,500	12,500 Added 1.54%	823,871 $1.26 Million
Q3 2024 Nov 14, 2024	BUY	$1.73 - $3.67 $1.21 Million - $2.56 Million	697,871 Added 614.86%	811,371 $1.61 Million
Q2 2024 Aug 14, 2024	BUY	$2.32 - $3.86 $165,648 - $275,604	71,400 Added 169.6%	113,500 $397,000
Q1 2024 May 15, 2024	BUY	$1.71 - $3.06 $5,301 - $9,486	3,100 Added 7.95%	42,100 $116,000
Q4 2023 Feb 14, 2024	SELL	$0.54 - $1.82 $2,430 - $8,190	-4,500 Reduced 10.34%	39,000 $66,000
Q3 2023 Nov 14, 2023	SELL	$0.97 - $1.8 $17,460 - $32,400	-18,000 Reduced 29.27%	43,500 $44,000
Q2 2023 Aug 14, 2023	SELL	$1.11 - $2.88 $1,554 - $4,032	-1,400 Reduced 2.23%	61,500 $71,000
Q1 2023 May 15, 2023	SELL	$1.51 - $3.25 $27,029 - $58,175	-17,900 Reduced 22.15%	62,900 $94,000
Q4 2022 Feb 14, 2023	BUY	$2.25 - $4.67 $121,725 - $252,647	54,100 Added 202.62%	80,800 $202,000
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $71,022 - $143,379	26,700 New	26,700 $113,000
Q1 2020 May 15, 2020	SELL	$10.23 - $24.56 $144,243 - $346,296	-14,100 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.42 - $26.61 $245,622 - $375,201	14,100 New	14,100 $331,000

Others Institutions Holding HRTX

# of Institutions

173

Shares Held

114M

Call Options Held

Put Options Held

32.4K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $205M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account